Artelo Biosciences, Inc. (NASDAQ: ARTL) has received a Notice of Allowance from the European Patent Office (EPO) for the commercial formulation of ART27.13, its injectable cannabinoid-based therapy currently in Phase 2 trials targeting cancer-related anorexia.
The patent covers formulations of ART27.13 dispersed in polyethylene glycol, protecting its intended commercial version. With patent protection extending until December 2041, this milestone significantly boosts the drug’s long-term commercial potential.
ART27.13, developed as a selective peripheral CB1/CB2 receptor agonist, aims to combat appetite loss and weight decline in cancer patients with minimal central nervous system side effects. Promising Phase 1 results demonstrated safety and early indicators of weight stabilization or gain in over 60% of participants, with Phase 2 (CAReS trial) results expected in Q3 2025.
The post Artelo Biosciences Secures European Patent Approval for ART27.13 Formulation appeared first on PRISM MarketView.
